Abzena Names Kimball Hall as Chief Operating Officer

Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on globalbankingandfinance.com is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies Sponsored Posts etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at globalbankingandfinance.com with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. Globalbankingandfinance.com also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites. Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. A very few articles on our website are sponsored posts or paid advertorials. These are marked as sponsored posts at the bottom of each post. For avoidance of any doubts and to make it easier for you to differentiate sponsored or non-sponsored articles or links, you may consider all articles on our site or all links to external websites as sponsored . Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.

Abzena announced today the appointment of Kimball Hall as Chief Operating Officer, adding to the companys executive leadership team.

Ms. Hall will focus on the growth of Abzena as the leading Partner Research Organization (PRO) for outsourced integrated gene to GMP services for large molecules and antibody drug conjugates. She joins Abzena from Genentech, a member of the Roche Group, a leading biopharmaceutical company. She stated, I am delighted to be joining Abzena and becoming part of this incredibly talented team. Abzenas strong track record in integrated development positions the company well as the worlds premier partner research organization. I look forward to helping our valued customers achieve successful outcomes through the scientific quality and speed of our integrated biologics capabilities.

Kimball served for 4 years at Genetech as SVP and Global Head of Drug Substance, as well as a member of the Genentech Executive Committee, with responsibility for 7 internal sites and 4,300 people covering both biologics and small molecules. Ms. Hall was also responsible for 27 external manufacturing locations. Her accomplishments included ensuring a strong Quality and Safety Culture, supporting 5 new commercial product launches, and establishing small volume production. Before joining Genentech, Ms. Hall served for 16 years at Amgen in multiple roles of increasing responsibility, culminating as VP of Manufacturing.

Ms. Hall holds a BS in Microbiology from the University of Washington. She has held a variety of Board and Advisory Board positions, including being a member of the Genentech Executive Committee, Genentechs Patient Access Board, and as an advisor to Genentechs Global Womens Professional organization.

Dr. Jonathan Goldman MD, CEO of Abzena commented, “I am delighted that Kimball is joining us. She brings exceptional experience in science, leadership and partnerships that are needed to advance our growth and enable our outstanding employee talent globally. Her collaborative approach to understanding and delivering for the unmet needs of our customers and the patients they serve makes her ideally suited to the Chief Operating Officer role.

Dr. Goldman added, “Abzena is the only organization able to deliver fully integrated gene to GMP in biologics, complex large molecules and ADC literally under one roof. We have shown great success in transitioning complex molecules through lead selection into clinical development in multiple therapeutic areas. Kimball is a unique and gifted leader. We are very fortunate to have her join our team and take us to the next level.”

About Abzena

Abzena provides the most complete set of solutions in integrated early discovery to mid-phase biotherapeutic and ADC drug development services in the pharmaceutical industry. The company maintains resources around the world, with facilities in the US and UK. Abzena is partnered with Welsh, Carson, Anderson & Stowe, one of the worlds leading private equity investors. For more information, please see www.abzena.com.

Joseph Reeds

[email protected]

01223 903367